Evaluation of the emergence of influenza virus resistance to neuraminidase inhibitors (NAIs) is now demanded following experience with amantadinamines. Preliminary data have indicated that ...

Aims In this study, we analyze the challenges involved in detecting novel neuraminidase inhibitors (NAIs) and offer strategies to overcome them with complementary bioassays. Materials & Methods We ...

Adding baloxavir marboxil (Xofluza) to neuraminidase inhibitors (NAIs), like oseltamivir (Tamiflu), was no better for preventing severe outcomes among patients hospitalized for flu compared with NAIs ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window With avian ...

Please provide your email address to receive an email when new articles are posted on . Influenza vaccines, masking and other infection prevention methods are effective control measures. Still, ...

Neuraminidase inhibitor (NI) dispensing has emerged as a possible automated data source for influenza surveillance. We aimed to evaluate its timeliness, correlation, and predictive accuracy in ...

Dr. Greg Poland answers the question: 'What AreTamiflu And Relenza?' May 27, 2009 -- Question:What are Tamiflu and Relenza? Answer:There are two different antiviral medications that can be used to ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

MSD has agreed to acquire Cidara Therapeutics in a $9.2bn deal, adding a new long-lasting infectious disease drug technology to its pipeline. The big pharma company will pay $221.50 per share in cash ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...